The US FDAd re-issued a decision first made in October that a shortage of the diabetes/weight-loss medication tirzepatide is ...

The obesity medication Zepbound can be used on-label to treat obstructive sleep apnea in adults with obesity, the FDA ...

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound will overtake competitors.

Tirzepatide treatment was associated with reduced body weight and diabetes risk across 3 years among individuals with obesity ...

Weight-loss injection Mounjaro, or tirzepatide, will be rolled out on the NHS gradually over a 12-year period, starting this year.

Zepbound (tirzepatide) is reshaping the competitive landscape in obesity treatment, challenging Novo Nordisk A/S' (NYSE:NVO) ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/95.C_N2kNfW.js ...

Obesity is more than a cosmetic concern. It’s a chronic disease that can be treated with drugs like semaglutide (Wegovy) and ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings ...

Check out all our end-of-year content—the latest Heart Sounds podcast reviews the reporters’ own favorite stories for 2024, ...